Anthony J. Olszanski, MD, RPh

Request an Appointment Online - Click Here

New patients can request an appointment online or call
888-FOX-CHASE

Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111

Video: Anthony J Olszanski, MD, RPh

Anthony J Olszanski, MD, RPh

Dr. Olszanski's
Patient Stories

Donna Piunt - Skin Cancer Patient Stories

Medical Oncology

Director, Clinical Pharmacology
Director, Medical Oncology Melanoma Program
Fox Chase Phase I Program
Senior Medical Advisor,
Cancer Genome Institute

Meet the other members of the
gastrointestinal cancer treatment team

Clinical Expertise:

Phase I trials, gastrointestinal cancer and melanoma

Certifications:

Medical Oncology
Clinical Pharmacology
Internal Medicine

I believe that the path towards treating any disease is best navigated by thoroughly understanding not only the disease, but also the patient. Good communication between a physician and a patient is especially critical in the treatment of cancer. Each patient has a right to be both respected and heard. In addition, relying on a team of experts to help manage the complexities of treating cancer is essential for success. As a physician, I strive to provide personalized and scientifically sound care to each of my patients.

My medical career started out as a pharmacist, specializing in oncology, where I prepared chemotherapy regimens and studied the effects the body has on drugs (pharmacokinetics). When I went to medical school, it was for the sole purpose of eventually becoming an oncologist. During my hematology/oncology and clinical pharmacology fellowships, I spent a great deal of time in early clinical development, with a goal of finding new effective therapies for patients with cancer. I honed my knowledge of drug discovery by spending five years in the pharmaceutical industry where I led multiple programs aimed at treating patients with cancers that didn’t respond to traditional chemotherapy. Today, my interests include early drug development for all types of cancers, and understanding how each medication may best be used. In addition I specifically focus on the treatment of gastrointestinal malignancies and melanoma.

In many situations, the best medical care a patient with cancer can get is on a clinical trial. These clinical trials offer patients potentially promising new therapies and very close follow up supplied by a team of experts. Fox Chase Cancer Center, with its leading-edge technology and dedicated medical professionals, offers numerous clinical trials and is helping to advance the care of all patients with cancer.

The staff at Fox Chase Cancer Center continually impress me with their unified commitment towards reducing the burden of cancer. When you step through the doors at Fox Chase Cancer Center, it is obvious that focusing on the patient is the top priority. I am proud to be a member of the caring community at FCCC, where oncology research and science is tailored and personalized for each patient.

Medical Education

Biostatistics, Dartmouth Medical School Center for Evaluative Clinical Sciences, Hanover, NH 2003;
MD, University of Medicine and Dentistry of New Jersey, Newark, NJ, 1996
BS Pharmacy, University of Montana, Missoula, MT, 1990

Residencies

Internal Medicine, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 1996-1999

Fellowships

Clinical Pharmacology/Toxicology Fellowship, Oncology Phase I Program, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 2002-2004;
Hematology/Oncology Fellowship, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 1999-2002

Professional Societies

American Society of Clinical Oncology;
American Board
of Clinical Pharmacology

Research Interests

Early clinical drug discovery trials (phase 1 trials)

Publications

Dr. Olszanski on PubMed

Peer Reviewed

Slingluff CL, Petroni GR, Molhoek KR, et al., and Olszanski AJ, Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial. JCO, In press

Twelves C, Chmielowska E, Havel L, et al., and Olszanski AJ, Randomized phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small cell lung cancer. In preparation

Martin LP, Kozloff MF, Herbst RS et al. and Olszanski AJ, Phase I study of axitinib combined with paclitaxel, docetaxel, or capecitabine in patients with advanced solid tumors. British Journal of Cancer, 107; 1268-1276, 2012

Kozloff MF, Martin LP, Krzakowski M et al. and Olszanski AJ, Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer, 107; 1277-1285, 2012

Rini BI, Schiller JH, Fruehauf J et al. and Olszanski AJ, Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy. Clinical Cancer Research, 17; 3841-3849, 2011

Michael MM, Vlahovic G, Khamly K, et al. and Olszanski AJ, Phase Ib study of CP-868,596, a PDGFR inhibitor, in combination with docetaxel with or without axitinib, a VEGFR inhibitor. British Journal of Cancer, 103(10); 1554-61, 2010

Schiller JH, Larson T, Ou IS, et al. and Olszanski AJ, Efficacy and Safety of Axitinib in Patients with Advanced Non-Small Cell Lung Cancer: Results from a Phase II Study. Journal Clinical Oncology, 27 (23); 3836-3841, 2009

Lewis NL, Lewis LD, Eder JP, et al. and Olszanski AJ, Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific PDGFR tyrosine kinase inhibitor in patients with advanced cancers. Journal Clinical Oncology, 27 (31); 5262-5269, 2009

Mita AC, Olszanski AJ, Walovitch RC, et al. Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel. Clinical Cancer Research, 13 (11);3293-3301, 2007

Perez RP, Lewis LD, Beelen AP, Olszanski AJ, et al. Modulation of Cell-cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01. Clinical Cancer Research, 12 (23); 7070-7085, 2006

Invited Papers/Editorials/Case Reports:

Chen K, Olszanski AJ, Farma J, Donor transmission of melanoma following renal transplant. Case Reports in Transplantation, In press

Skarbnick, AP, Olszanski AJ, Does the order of factors affect the product? Lessons learned from the TORCH trial. Transl Lung Cancer Res Sep 20, 2012. DOI: 10.3978/j.issn.2218-6751.2012.09.09

Patson B, B Cohen R, Olszanski, AJ, Pharmacokinetic evaluation of axitinib. Expert Opinions in Drug Metabolism and Toxicology, 8 (2); 259-270, 2012

Olszanski AJ, Rigas JR, Docetaxel and gemcitabine: A non-platinum combination for non-small cell lung cancer. Clinical Lung Cancer, 1(S1):15-19, 2000

Selected Abstracts

Rixe O, Puzanov I., LoRusso P, et al and Olszanski AJ, Dose-escalation Phase 1 study of cabazitaxel (Cbz) + gemcitabine (Gem) in patients (pts) with metastatic or unresectable advanced solid malignancy. ESMO (2012) Abstract 497P

Slingluff CL, et al and Olszanski AJ, Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: Phase II trial with correlative studies. ASCO (2012) Abstract 8530

Astsaturov IA, et al and Olszanski, AJ, A phase 1 evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction. ASCO (2012) Abstract 74

Faivre S, Olszanski AJ, et al. Phase 1 and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors. ASCO (2012) Abstract 2554

Mendelson DS, et al. and Olszanski AJ, First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor. ASCO (2011) Abstract 3055

Kozloff MF, et al. and Olszanski AJ, Axitinib (AG-013736) Combined with Paclitaxel/Carboplatin, Gemcitabine/Cisplatin, or Pemetrexed/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer and Other Solid Tumors. 13th WCLC (2009) Abstract 7656; Oral presentation

Martin L, et al. and Olszanski AJ, Phase I Study of Axitinib (AG-013736) in Combination with Chemotherapy in Patients with Advanced Solid Tumours. ESMO (2008) Abstract 472P; Poster

Rini BI, et al and Olszanski AJ, Association of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). ASCO (2008) Abstract 3543; Oral presentation

Michael MM, et al. and Olszanski AJ, Phase Ib study of CP-868,596, a PDGFR inhibitor, in combination with docetaxel (Doc) with or without AG-013736, a VEGF inhibitor. ASCO (2008) Abstract 3549; Poster

Lewis LD, Reddy NJ et al. and Olszanski AJ, Pharmacokinetics of an Oral Film-coated Tablet of CP-868,596,a PDGFR Inhibitor, in Patients with Advanced Cancers. ACR/NCI/EORTC (2008) Abstract 585; Poster

Schiller JH, et al. and Olszanski AJ, Efficacy and safety of axitinib in patients with advanced non-small cell lung cancer: a phase II trial. ASCO (2007) Abstract 7507; Oral presentation

Cohen RB, et al. and Olszanski AJ, Axitinib (AG-013736) in combination with paclitaxel/carboplatin in patients with advanced solid tumors. AACR/NCI/EORTC (2007) Abstract A157; Poster

Michael M, et al. and Olszanski AJ, Phase 1b study of oral CP-868,596, a highly specific PDGFR inhibitor, in combination with docetaxel. ACR/NCI/EORTC (2007) Abstract A148; Poster

Lewis N, et al. and Olszanski AJ, Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of Oral CP-868,596, a Highly Specific PDGFR Inhibitor in Patients with Advanced Cancers. AACR/NCI/EORTC (2005) Abstract A228; Oral Discussion Poster

Olszanski AJ, et al. Phase 1 and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system (HDDS) for paclitaxel. ASCO (2004) Abstract 2048; Poster

Olszanski AJ, Lewis LD. Molt-4 rho(0) cells up regulate stress-induced survival genes in an attempt to overcome the potentially lethal consequence of mitochondrial DNA depletion. ASCPT (2004) Abstract; Poster PI-54

Olszanski AJ, Lowrey CH, Sporn MB, Suh N. The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO) Inhibits Proliferation and Induces Apoptosis of Myeloma Cells in a Time and Dose-Dependent Fashion. Blood 100(11):816a (2002) Abstract 3224; Poster 644

Olszanski AJ, Lowrey CH, Sporn MB, Suh N. Human hematopoietic colony formation is highly sensitive to the novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid. Blood 98(11):119b (2001) Abstract 4128

Eyer CL, Olszanski AJ, Smith JR, Anderson AC, and Irem SO. Effects of Perfluorodecalin and Perfluorooctylbromide emulsions on peak contractile force and ATP levels in the guinea pig left atrium. Biomat. Artif. Cells Artif. Org. 19(4):719-729 (1991)

Olszanski T, and Eyer CL. Effect of perfluorocarbon emulsions on contractility of oxygen-deprived guinea pig atria. Proc. West. Pharmacol. Soc. 33:149-151 (1990)

Olszanski AJ. Perfluorochemical Applications. Clerks Comments, University of Montana, School of Pharmacy. (1990)

Olszanski T and Eyer CL. Protection of Cardiac Contractility from Hypoxia by a Perfluorocarbon Emulsion. Proc. Mont. Acad. Sci. 49:171-176 (1989)